KalVista Pharmaceuticals, Inc. (KALV) Dividend History

KalVista Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of novel, oral protease inhibitors for the treatment of hereditary angioedema (HAE) and other medical conditions. Founded in 2009 and based in the United States, the company aims to advance targeted therapies to improve patient outcomes through innovative drug development and clinical programs.

55 Cambridge Parkway, Cambridge, MA, 02142
Phone: (857) 999-0075

Dividend History

KalVista Pharmaceuticals, Inc. currently does not pay dividends

Company News

  • Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

    The angioedema treatment market is expected to grow due to the rising prevalence of allergic conditions and increasing awareness of hereditary angioedema (HAE). The pipeline analysis shows over 15 companies are developing 20+ angioedema drugs, with promising therapies in different clinical trial phases.

    GlobeNewswire Inc.
    Featured Companies: ATXS CAMP IONS NTLA
  • Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for CrowdStrike Holdings, Inc. (NASDAQ: CRWD) from $318 to $375. Keybanc analyst Eric Heath maintained an Overweight rating. CrowdStrike shares rose 0.4% to close at $322.44 on Tuesday. See how other analysts view this stock. Piper Sandler boosted Shopify Inc. (NYSE: SHOP) price target from $56 to $63. Piper Sandler analyst Clarke Jeffries maintained an Underweight rating. Shopify shares fell 13.4% to close at $77.18 on Tuesday. See how other analysts view this stock. Needham boosted the price target for SS&C Technologies Holdings, Inc. (NASDAQ: SSNC) from $62 to $70. Needham analyst Mayank Tandon maintained a Buy rating. SS&C Technologies shares fell 1.8% to close at $60.15 on Tuesday. See how other analysts view this stock. JP Morgan raised Bruker Corporation ...

    Benzinga
    Featured Companies: BIIB BRKR C CRWD DENN HPQ MDB SHOP SSNC
  • Insiders Buying Monro And 3 Other Stocks

    Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. KalVista Pharmaceuticals The Trade: KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) 10% owner Nimish P Shah acquired a total of 86,048 shares an ...

    Benzinga
    Featured Companies: LEE MNRO POST
  • $10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying

    Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Vera Therapeutics The Trade: Vera Therapeutics, Inc. (NASDAQ: VERA) Director Maha Katabi acquired a total of 161,290 shares an average price of $31.00. To acquire these shares, it cost around $5 million. What’s Happening: Vera Therapeutics priced its upsized public offering of ...

    Benzinga
    Featured Companies: AVBP CLF VERA
  • Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying

    Although U.S. stocks closed higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. KalVista Pharmaceuticals The Trade: KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) 10% owner Nimish Shah acquired a total of 91,804 shares an ...

    Benzinga
    Featured Companies: FBK NCDL
Dividend data last updated 06/07/2025 20:23:38 UTC